Latest News and Press Releases

Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada Primary efficacy endpoint indicates excellent contraceptive efficacy, with a Pearl Index...

PRESS RELEASE mithra announces positive OUTCOME of myring(TM) COMMERCIAL BATCH bioequivalence study Bioequivalence study performed on commercial Myring(TM) batch produced at Mithra CDMO Data...

PRESS RELEASE MITHRA COMPLETES RECRUITMENT FOR estelle® phase iii study in US & Canada Estelle® Phase III study in US/Canada remains on track to report top line data in Q1 2019 Study...

PRESS RELEASE MIThRA ANNOUNCES completion of recruitment in donesta® PhAse II study Donesta® Phase II study remains on track to report top line data late Q1 2018 260 women recruited in...

PRESS RELEASE MIThRA'S MARKETING AUTHORIZATION APPLICATION FOR TiBELIA® ACCEPTED BY HEALTH CANADA Tibelia® would be the first tibolone-based Hormone Therapy product available in Canada ...

Regulated information MIThRA ANNOUNCES 2017 HALF YEAR RESULTS Liège, Belgium, 21 September 2017 - Mithra (Euronext Brussels: MITRA), a company specialized in women's health, today announces...

MIThRA ANNOUNCES first subject completes  ESTELLE® PhAse III study Estelle® Phase III studies remain on track to report top line results in Q3 2018 and Q1 2019 in Europe/Russia and the...

PRESS RELEASE ReCRUITMENT COMPLETED IN Estelle® population PK substudy Study to determine impact of demographic characteristics on the absorption, distribution and excretion of Estelle® ...

PRESS RELEASE MITHRA StRENGTHENS E4 PATENT POSITION in australiaN MARKET Patents granted for Estetrol (E4) synthesis protect manufacturing process until 2032 Certificate of grant covers...

 Mithra signs EXclusive license and supply agreement with FUJI Pharma for donesta® in japan and asean               Fuji Pharma obtains rights to commercialize Donesta®, Mithra's Hormone Therapy...